Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

473
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
473
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

108
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
108
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
126

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Cardiovascular drug development: role of Mendelian randomization.

European heart journal·2026
Same author

Lifestyle characteristics and plasma biomarkers for risk of MASLD differ by sex in the general population.

European journal of internal medicine·2026
Same author

High Body Mass Index as a Causal Risk Factor for Vascular-Related Dementia: A Mendelian Randomization Study.

The Journal of clinical endocrinology and metabolism·2026
Same author

Impact of Variation in APOE on Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Sequencing and Genotyping in General Population Cohorts.

ACR open rheumatology·2026
Same author

Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease.

Atherosclerosis·2025

Related Experiment Video

Updated: May 16, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.5K

Target Populations for Novel Triglyceride-Lowering Therapies.

Ask T Nordestgaard1, Anne Tybjærg-Hansen2, Hank Mansbach3

  • 1Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Clinical Biochemistry and the Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.

Journal of the American College of Cardiology
|May 14, 2025
PubMed
Summary
This summary is machine-generated.

New drugs targeting lipoprotein lipase activity, such as apolipoprotein C-III and angiopoietin-like protein inhibitors, effectively lower triglycerides and remnant cholesterol. These therapies show promise for preventing acute pancreatitis and metabolic dysfunction-associated steatohepatitis.

Keywords:
MASHMASLDNAFLDVLDLchylomicronliver diseasemyocardial infarctionperipheral artery diseasestroketriglyceride-rich lipoprotein

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Related Experiment Videos

Last Updated: May 16, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.5K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Lipoprotein lipase (LPL) is crucial for triglyceride hydrolysis and remnant lipoprotein clearance.
  • Dysregulation of LPL activity is implicated in hypertriglyceridemia, acute pancreatitis, cardiovascular disease, and metabolic dysfunction-associated steatohepatitis (MASH).
  • Novel therapeutic strategies aim to enhance LPL activity to mitigate these conditions.

Purpose of the Study:

  • To review emerging drug classes that increase LPL activity for treating dyslipidemias.
  • To examine the evidence supporting apolipoprotein C-III (APOCIII) and angiopoietin-like protein (ANGPTL) 3, 3/8, and 4 inhibitors.
  • To discuss fibroblast growth factor-21 (FGF21) analogues as a related therapeutic approach.

Main Methods:

  • Review of clinical trials and epidemiological/genetic studies on triglyceride- and remnant cholesterol-lowering agents.
  • Analysis of drug development pipelines targeting APOCIII and ANGPTLs.
  • Evaluation of FGF21 analogues for metabolic and cardiovascular indications.

Main Results:

  • APOCIII inhibitors are approved for reducing acute pancreatitis risk in severe hypertriglyceridemia.
  • ANGPTL inhibitors demonstrate significant triglyceride and remnant cholesterol reduction.
  • FGF21 analogues show efficacy in reducing hepatic steatosis and fibrosis in MASH patients.

Conclusions:

  • APOCIII inhibitors and ANGPTL inhibitors offer potent triglyceride- and remnant cholesterol-lowering effects.
  • These novel agents are valuable for managing severe hypertriglyceridemia and MASH.
  • Further research is needed to confirm their role in preventing atherosclerotic cardiovascular disease.